Molbio Diagnostics Limited has submitted its Monitoring Agency Report for the quarter ended September 30, 2026. The report, issued by CRISIL Ratings Limited, confirms the utilization of proceeds from its Initial Public Offering (IPO) towards funding capital expenditure for infrastructure development and equipment procurement. The company has allocated ₹1,055.35 million for setting up a research and development facility and ₹722.81 million for plant and machinery.
Molbio Diagnostics Reports IPO Fund Utilization
Molbio Diagnostics Limited has officially disclosed its Monitoring Agency Report, detailing the utilization of funds raised through its Initial Public Offering (IPO) for the quarter ended September 30, 2026. The report, prepared by CRISIL Ratings Limited, confirms that the proceeds are being used in accordance with the objects outlined in the offer document.
Key Utilizations Detailed
The primary utilization of the IPO proceeds has been directed towards significant capital expenditure. A sum of ₹1,055.35 million has been allocated for the establishment of a new research and development facility and a Center of Excellence, which will be operated by its wholly-owned subsidiary, Bigtec. This includes connected office space for the company and its subsidiaries.
Additionally, ₹722.81 million is being invested in the procurement, installation, and commissioning of plant, machinery, and other equipment for its facilities in Goa Unit I, Goa Unit II, and Visakhapatnam Unit. These investments are intended to enhance manufacturing efficiency, product quality, and regulatory compliance.
Financial Oversight and Reporting
The report indicates that the total gross proceeds from the IPO were ₹2,000.00 million, with issue expenses amounting to ₹127.19 million, resulting in net proceeds of ₹1,872.81 million. The Monitoring Agency confirmed that the utilization of funds is as per the disclosures in the Offer Document, with no major deviations observed. The company also reported that unutilized proceeds are invested in fixed deposits, earning interest income.
The report was reviewed and taken on record by the Audit Committee and the Board of Directors of Molbio Diagnostics Limited on November 05, 2026.
Source: BSE
